Dacarbazine

CHEMBL476 Phase 4 Aprobado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
182.2 g/mol
LogP
-0.6
Phase
4

A chemotherapy agent used to treat melanoma, Hodgkin's lymphoma, and soft tissue sarcomas by alkylating DNA and disrupting its replication in cancer cells. It requires metabolic activation in the liver to become its active form. Common side effects include severe nausea, vomiting, and bone marrow suppression.

Peso molecular

182,1800 g/mol

LogP

-0,60

TPSA

99,70 Ų

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estructura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN(C)/N=N/c1[nH]cnc1C(N)=O

InChI

InChI=1S/C6H10N6O/c1-12(2)11-10-6-4(5(7)13)8-3-9-6/h3H,1-2H3,(H2,7,13)(H,8,9)/b11-10+

Molecular Formula

C6H10N6O

HBD / HBA

2 / 5

Enlaces Rotables

3

Átomos Pesados

13

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

A chemotherapy agent used to treat melanoma, Hodgkin's lymphoma, and soft tissue sarcomas by alkylating DNA and disrupting its replication in cancer cells. It requires metabolic activation in the liver to become its active form. Common side effects include severe nausea, vomiting, and bone marrow suppression.

Yes, Dacarbazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL476. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 135398738. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.